ViGenCell

308080 · KOSDAQ · ₩308080 · 바이젠셀

₩4,870▼ ₩170 (3.37%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩3,400

vs the current price (₩4,870)

Enterprise value
₩47B
Equity value
₩70B
WACC
8.9%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩3,570
−26.7%
Base
₩3,400
−30.2%
Bull
₩2,968
−39.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (−20.0%).

Revenue growth

  • -10%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.

  • -6.7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.

  • -3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.

  • -0.2%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.

Business

  • -20%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 6,372.1%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 3,215.8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • -10%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.89

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.83, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩922M
Net debt (borrowings and leases − cash and deposits)
−₩22B
+ Stakes and investments
₩800M
Associates, long-term financial assets and deposits (book value)
Shares
20,499,260
Share price
₩4,870
Market cap
₩100B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩0₩279M₩23M₩830M₩774M₩747M₩746M₩768M
Growth——−91.9%−10.0%−6.7%−3.5%−0.2%3.0%
EBIT−₩20B−₩15B−₩17B−₩166M−₩155M−₩149M−₩149M−₩154M
EBIT margin—−5,487.2%−75,453.1%−20.0%−20.0%−20.0%−20.0%−20.0%
After-tax EBIT−₩14B−₩11B−₩12B−₩120M−₩112M−₩108M−₩108M−₩111M
+ Depreciation₩3.3B₩3B₩2.6B₩53B₩49B₩48B₩48B₩49B
− Capital spending——₩729M₩27B₩25B₩24B₩24B₩25B
− Working capital−₩61B₩135M−₩981M₩9.2M₩5.6M₩2.7M₩149,418−₩2.2M
Free cash flow——−₩9.5B₩26B₩24B₩23B₩23B₩24B
Discount factor———0.9180.8430.7740.7110.653
Present value———₩24B₩21B₩18B₩17B₩16B

Terminal value −₩74B, worth −₩48B today: -103% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩1,892 a share)Now 2.57×₩1,8620.98×₩2,9381.55×₩5,8943.11×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
7.9%₩3,434₩3,230₩2,992₩2,710₩2,371
8.4%₩3,589₩3,417₩3,217₩2,983₩2,706
8.9%₩3,718₩3,569₩3,400₩3,204₩2,974
9.4%₩3,823₩3,695₩3,550₩3,383₩3,191
9.9%₩3,911₩3,799₩3,673₩3,531₩3,367

Now (TTM)

Market cap
₩100B
Enterprise value
₩78B
P/E
—
P/B
2.6×
P/S
108.3×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩9,750₩2,500₩5,850₩7,120₩18,463
Market cap₩200B₩51B₩120B₩146B₩378B
P/E—————
P/B4.6×0.9×1.7×1.6×3.6×
P/S8,814.7×183.7×———
EV/EBITDA—————
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
ViGenCell—2.6×108.3×—0.0%
Samsung Biologics31.9×7.6×13.9×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen79.4×28.6×60.3×—0.1%
SK biopharmaceuticals15.2×6.0×7.1×—0.0%
Yuhan23.2×2.3×2.4×30.2×0.8%
HLB—15.4×54.3×—0.0%
Similar companies (median)27.9×6.8×11.4×30.2×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: ViGenCell / 바이젠셀 / 308080 / KRX:308080

Source: KRX statistical information